Brand Name | Status | Last Update |
---|---|---|
clariscan | ANDA | 2024-09-17 |
dotarem | New Drug Application | 2025-03-14 |
gadoterate meglumine | ANDA | 2024-10-27 |
Code | Description |
---|---|
A9575 | Injection, gadoterate meglumine, 0.1 ml |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast diseases | D001941 | — | N60-N65 | 1 | — | — | 1 | — | 2 |
Magnetic resonance imaging | D008279 | — | — | — | — | — | 1 | 1 | 2 |
Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | 1 | 2 |
Renal insufficiency | D051437 | — | N19 | — | — | — | 2 | — | 2 |
Cognition | D003071 | EFO_0003925 | — | — | — | — | 1 | — | 1 |
Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | 1 | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | 1 | — | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cerebral arterial diseases | D002539 | EFO_1000859 | — | — | — | 2 | — | — | 2 |
Central nervous system diseases | D002493 | — | G96.9 | — | — | 1 | — | — | 1 |
Nervous system diseases | D009422 | — | G00-G99 | — | — | 1 | — | — | 1 |
Self-assessment | D012647 | — | — | — | — | 1 | — | — | 1 |
Diagnostic self evaluation | D059026 | — | — | — | — | 1 | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
Retinal diseases | D012164 | — | H35.9 | — | — | 1 | — | — | 1 |
Renal artery obstruction | D012078 | EFO_1001150 | N28.0 | — | — | 1 | — | — | 1 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Fibroadenoma | D018226 | — | — | 1 | — | — | — | — | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myocardial perfusion imaging | D055414 | — | — | — | — | — | — | 1 | 1 |
Brain diseases | D001927 | — | G93.40 | — | — | — | — | 1 | 1 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Drug common name | Gadoterate meglumine |
INN | — |
Description | Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (gadoterate meglumine). The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it has magnetic properties, gadoteric acid develops a magnetic moment when put under a magnetic field, which increases the signal intensity (brightness) of tissues during MRI imaging.
|
Classification | Small molecule |
Drug class | gadolinium derivatives (principally for diagnostic use) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 72573-82-1 |
RxCUI | — |
ChEMBL ID | CHEMBL2219415 |
ChEBI ID | 73727 |
PubChem CID | 158536 |
DrugBank | DB09132 |
UNII ID | — |